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ABSTRACT 
Acute Kidney Injury (AKI) is defined as a sudden decrease in the kidneys' ability to filtrate 
waste products and excrete excess water. Detecting AKI primarily relies on measuring the 
increased concentration of function markers (i.e., creatinine and cystatin C) and even 
measuring urine output.  
 
This thesis aimed to investigate the performance of kidney function markers in patients 
during critical illness. To study the variations of the function markers in an ICU population 
and to examine the performance of the most commonly used estimated glomerular filtration 
equations. In addition, to investigate the associations between creatinine and cystatin C and 
long-term mortality and to identify factors predictive of renal dysfunction after ICU 
discharge.  
 
Both creatinine and cystatin C are within the normally acceptable limits of daily variation 
which means that changes in function markers between sampling-times during the day are 
likely to indicate a change in the biomarker levels due to the disease or treatment.  
Combination of both creatinine and cystatin C enables the best agreement between estimated 
and measured glomerular filtration rate. Levels of cystatin C after critical illness is strongly 
associated with 90-day and 1-year mortality in both AKI and non-AKI patients. Creatinine, 
on the other hand, has little value as a prognostic marker in the majority of patients. The 
incidence of CKD (eGFR<60) in ICU patients three months after AKI was 25.8% when using 
creatinine-based eGFR and 63.7% using cystatin C-based eGFR. Creatinine-defined CKD at 
follow-up was predicted by age, discharge cystatin C, discharge creatinine, and female sex. 
Cystatin C-defined CKD at follow-up was predicted by age, discharge cystatin C, CRRT in 
ICU, and diabetes. 
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1 INTRODUCTION 
Acute kidney injury (AKI) is defined as an acute decline in the kidneys’ ability to filter water 
and waste products. The resulting increase in metabolites, e.g. creatinine and cystatin C is 
what forms the basis for how kidney function is measured and thereby diagnosed.  
Though intense and ongoing research on the topic of kidney biomarkers is being conducted, 
most hospitals and outpatient clinics and still use creatinine, urea, and urine output as a 
measure of kidney function. Some clinics have introduced cystatin C as a supplement.  
AKI is common during critical illness. It is unclear how these commonly used kidney 
biomarkers are affected in patients during the time in the intensive care unit.  
Considering the most apparent effects of an ICU admission: circadian confusion caused by 
the ICU milieu, the physiological stress to the body and organs of critical illness, the 
treatment therapies, and the extensive muscle wasting. No organ goes free not even the 
kidney. 
The aim of this thesis is thus to further investigate the kidney function markers among critical 
ill patients. 
 
2 BACKGROUND 
2.1 DEFINITION OF ACUTE KIDNEY INJURY 
Acute kidney injury is a syndrome characterized by a sudden reduction in glomerular 
filtration rate (GFR). AKI leads to an increase in waste products including the commonly 
measured creatinine as well as cystatin C and urea.  
Though kidney injury has been known for a long period of time, it was not until 2004 that the 
first successful consensus definition emerged. The definition was known as RIFLE (Risk, 
Injury, Failure, Loss of kidney function, and End-stage renal disease) published by the Acute 
Dialysis Quality Initiative[1]. Simultaneously the term acute renal failure was changed to 
acute kidney injury in an effort to nuance the spectrum of disease.  
The RIFLE criteria were revised by the Acute Kidney Injury Network (AKIN) in 2007 
further improving the sensitivity of the diagnostic tool[2]. 
The latest definition is a unification of both the RIFLE and AKIN criteria presented in 2012 
by the Kidney Disease: Improving Global Outcomes (KDIGO)[3]. 
The definitions are shown in Table 1. 
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Table 1. Consensus definitions of AKI[4].  
 
 
Acute Kidney Disease (AKD) proposed in 2017 by ADQI to describe prolonged renal 
dysfunction after AKI and prior to chronic kidney disease. AKD is considered present if 
KDIGO-AKI stage 1 or higher is fulfilled during a period of 7 to 90 days after the debut of 
AKI[5, 6].  
Chronic Kidney Disease (CKD) defined by KDIGO guidelines in 2012 as "Abnormality of 
kidney structure or function, present for more than three months, with implications for 
health"[3].  
End Stage Renal Disease (ESRD) is defined as a severe chronic renal disease with either 
estimated GFR less than 15ml/min/1.73m2 or dialysis dependence. Though this definition is a 
hard endpoint and incidences widely reported in local and national registers it is still 
disputed[7]. 
greater proportion of patients to be classified as having AKI.
Requiring progressively larger increases in serum creatinine
to meet diagnostic criteria as the baseline rises as in the above
criteria reduces this potential for bias. Using these criteria,
Hsu et al. reported that the community-based incidence of
non-dialysis AKI increased from 3227 to 5224 per million
Table 1 | Evolution of consensus definitions for AKI
Criteria RIFLE25 AKIN26 KDIGO27,92
Date of
release 2004 2007 2012
Baseline Not specifically defined. If not available, back-
calculate a serum creatinine using an eGFR of
75ml/min/1.73m2 using the MDRD equation
48-h window Not specifically defined. If not available, use lowest
serum creatinine during hospitalization, or calculate
SCr using MDRD assuming baseline eGFR 75ml/
min/1.73m2 when there is no evidence of CKD
Time interval Diagnosis and staging: within 1–7 days and
sustained more than 24h
Diagnosis: within 48h
Staging: 1 week
Diagnosis: 50% increase in SCr within 7 days or
0.3mg/dl (26.5mmol/l) within 48 h
Criteria Creatinine Urine output
Creatinine (urine output
criteria same)
Creatinine (urine output
criteria same)
Stage Risk Increased SCr 1.5–1.9 times baseline
or GFR decrease 425%
o0.5ml/kg/h for
6–12h
1 Increased SCr 1.5–1.9 times
baseline
OR
X0.3mg/dl (X26.5mmol/l)
increase
1 Increased SCr 1.5–1.9 times
baseline (7 days)
OR
X0.3mg/dl (X26.5mmol/l)
increase (48h)
Injury 2.0–2.9 times baseline or GFR
decrease 450%
o0.5ml/kg/h for
X12h
2 Same as RIFLE minus
eGFR criteria
2 same as AKIN
Failure 3.0 times baseline, GFR decrease
475%, or SCr
X4.0mg/dl (354mmol/l) with an
acute rise of X0.5mg/dl (44mmol/l)
o0.3ml/kg/h for
X24h
OR
Anuria for X12h
3 Same as RIFLE or on RRT.
eGFR criteria removed
3 3.0 times baseline,
OR
Increase in SCr X4.0mg/dl
(354mmol/l)
OR
Initiation of renal replacement
therapy
OR
For o18 years, decrease in
eGFR to o35ml/min per
1.73m2
Loss Persistent ARF¼ complete loss of
kidney function (need for dialysis)
44 weeks
Notable differences:
(1) Addition of 0.3mg/dl absolute
change in SCr to increase diag-
nostic sensitivity
(2) eGFR criteria removed
(3) 48-h time window to ensure
acuity (also allows for inpatient
baseline values)
(4) Exclusion of Loss/ESKD cate-
gories as diagnostic criteria
Notable differences:
(1) Time frame differences for
absolute versus relative
changes in serum creatinine
(2) 0.5mg/dl increase for those
with SCr X4.0mg/dl
(354mmol/l) no longer
required if minimum AKI
threshold met
(3) Inclusion of eGFR criteria for
children
ESKD End-stage kidney disease
(43 months)
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ARF, acute renal failure; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney
disease; ESRD, end-stage renal disease; MDRD, Modification of Diet in Renal Disease; KDIGO, Kidney Disease: Improving Global Outcomes; RIFLE, Risk, Injury, Failure, Loss,
and End-stage Kidney Disease; SCr, serum creatinine.
Table 2a |Hospital-based incidence rates of AKI for cardiac surgery before and after RIFLE/AKIN/KDIGO
Study Era Country Enrollment Setting Definition of AKI Incidence
Chertow et al.134 Before USA (Veterans Affairs) 1987–1994 Cardiac surgery RRT 1.1%
Mangano et al.135 RIFLE AKIN KDIGO USA 1991–1993 Cardiac surgery Postoperative serum creatinine
42mg/dl with at least a
0.7mg/dl increase from
preoperative levels.
7.7%
Lenihan et al.75 USA (National Hospital
Discharge Survey)
1999–2008 Cardiac surgery ICD-9 Codes for ARF 7.7%
Hobson et al.136 After USA (Florida) 1992–2002 Cardiothoracic surgery RIFLE 43%
Dasta et al.137 RIFLE AKIN KDIGO USA (Pittsburgh) 1998–2002 Cardiac surgery (CABG) RIFLE 6.9%
Kuitunen e al.138 Finland (Helsinki) 2003 Cardiac surgery RIFLE 19.3%
Kidney International (2015) 87, 46–61 49
ED Siew and A Davenport: Growth of acute kidney injury rev i ew
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2.2 INCIDENCE AND OUTCOMES  
The incidence of AKI varies in the literature depending on the populations studied, and which 
definitions used.  
In the ICU the incidence is increasing[8-10]. In a meta-analysis (data from 2004 to 2012) 
from 2013, Susantitaphong showed, using the KDIGO definition, that 20% of adults and 33% 
of children developed AKI during hospitalization[11]. A study[12] with more than 18 million 
patients with AKI from 2001 to 2011reported an almost fivefold increase in incidence.  
Possible explanations are the wider-reaching definitions and increased awareness amongst 
clinicians and researchers. Additional factors include aging populations, nephrotoxic drugs 
and treatment regimes, and perhaps even the subtle changes in medical ethics over the 
years[11, 13, 14].  
A Swedish study from 2015 showed that patients with de novo AKI in ICU suffered one-year 
mortality of 49% while 2% of survivors were dependent on renal replacement therapy[15].   
  
2.3 BIOMARKERS OF RENAL FUNCTION 
Renal function is usually expressed in terms of glomerular filtration rate. GFR measures the 
volume of plasma that is cleared of a substance per unit time (ml/min). Usually GFR is 
corrected to a standard body surface area of 1.73m2 [16]. The ability to accurately quantify 
GFR in critically ill patients remains challenging.  
Plasma creatinine is the dominant endogenous marker of GFR used to diagnose and stratify 
AKI[3]. In addition to being a surrogate measurement of GFR, the plasma creatinine 
concentration is a function of muscle mass. It is produced from breakdown of creatine-
phosphate mainly in skeletal muscles. It is almost freely filtered but also secreted in the 
tubuli. This being a particular important factor in critically ill patients where continuing loss 
of muscle mass leads to a parallel decline in plasma creatinine levels and hence a progressive 
underestimation of true GFR[17].    
 
Measurement of GFR 
Measuring GFR using exogenous tracers can be achieved with iohexol, inulin, 99Tm-DTPA, 
iothalamate, and 51Cr-EDTA. Inulin has traditionally been viewed as the golden standard, 
but iohexol is on par[18]. 
In the case of the single injection technique, a series of blood samples is taken at specific time 
intervals afterward thereby allowing for plotting and calculating both the faster distribution- 
and the slower elimination-phase[19, 20]. Less exact techniques have been developed where 
fewer (3 - 5) or even only a single blood sample is needed after injection of, in this case, 
 10 
iohexol. These techniques are most likely spurred on to minimize the cost and the time-
consuming process of a multisample GFR measurement.  
The two-compartment method where multiple blood samples obtained both before and after 
the tracer is completely mixed with the entire distribution volume is considered the most 
accurate method for measuring GFR using iohexol[21].  
Since the use of exogenous markers for measuring GFR is time-consuming and impractical, it 
is hardly useful in the clinical setting. 
 
Estimation of GFR 
Creatinine 
Creatinine is a 113 Da amino acid byproduct of the breakdown of creatine phosphate in 
muscle. Muscle tissue is the primary source of creatine with contribution from dietary intake 
and liver synthesis. It is not protein-bound and is distributed throughout the total volume of 
body water. Creatinine excretion is primarily via glomerular filtration where it is freely 
filtered but also secreted in the tubuli. Approximately 15% is actively secreted by the tubuli, 
and a small amount is eliminated in the intestines[22].  
Creatinine is used worldwide as an endogenous marker for estimating GFR and several eGFR 
equations exist (Tables 2-4).  
The use of creatinine-based eGFR formulas with ICU patients should warrant some concerns. 
The rapid muscle wasting in critically ill patients reduces the main reservoir of creatine[23]. 
Even substantial reduction in true GFR can be compensated by increased tubular secretion 
and compensatory hyperfiltration[24]. Rapid changes in GFR will not show in creatinine 
concentration because of its large distribution volume.  
Endogenous creatinine has been used to estimate GFR since the time of the Second World 
War, and it is still being used. Probably with good right, in many cases, it delivers a good 
estimate of the GFR in stable and physically active patients. However, it is probably not to be 
preferred for use in a population of critically ill patients in the ICU and where early diagnosis 
of AKI is needed. 
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Cystatin C 
Cystatin C is a 13 kDa enzyme inhibitor involved in protein catabolism and is considered to 
be produced by all nucleated cells at an almost constant rate.  
Elimination from blood is almost exclusively by glomerular filtration[25]. In healthy 
individuals, cystatin C is freely filtrated and subsequently completely reabsorbed and 
catabolized by proximal renal tubules and therefore undetectable in urine. 
Cystatin C is believed to be a more sensitive marker for GFR than creatinine and has been 
shown to detect AKI one to two days earlier[26-28]. The plasma levels of cystatin C are 
affected by Glucocorticoid treatment which increases plasma levels in a dose-dependent 
manner, and thyroid function where hypothyroid patients have lower levels of cystatin C and 
hyperthyroid patients have higher levels of cystatin C in plasma.  
It has been demonstrated that plasma cystatin C gradual increases during ICU admission in 
patients with and without AKI[29]. Carlier et al. confirmed that cystatin C based GFR 
equations systematically underestimated inulin clearance in critically ill patients after a 
median ICU length of stay of seven days[30].   
Iohexol 
Iohexol is an iodine-based liquid with low osmolality. In Sweden the most common trade 
name is Omnipaque. Among other it is used as a contrast agent for radiological examinations. 
Ironically radiocontrast medium is one of the most common causes of AKI in ICU patients.  
It is considered essentially free from side effects in low doses [31-33]. Elimination from 
blood happens by glomerular filtration with no signs of tubular secretion or reabsorption. 
Because of this it is well suited as a marker for GFR.  
When used for measuring GFR the doses of iohexol are 10 – 50 times lower than those used 
in radiographic examinations, reducing the risk of side effects. Iohexol has been used for 
GFR measurement in Sweden for more than 15 years. 
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Table 2. Creatinine based eGFR equations 
Creatinine equations 
MDRD 
Female: 175 * (pCrea/88.4)– 1.154 * Age– 0.203 * 0.742  
Male: 175 * (pCrea/88.4)– 1.154 * Age– 0.203 
Revised Lund-Malmö creatinine equation[34] (LM-REVcrea)  
Exp[X-0.0158 * Age + 0.438 * Ln[Age]] 
Female: pCr < 150: X = 2.50 + 0.0121 * (150 - pCrea) 
Female: pCr ≥ 150: X = 2.50 – 0.926 * Ln[pCrea/150] 
Male: pCr < 180: X = 2.56 + 0.00968 * (180 - pCrea) 
Male: pCr ≥ 180: X = 2.56 – 0.926 * Ln[pCrea/180] 
CKD-EPI creatinine equation for Caucasians[35] (CKD-EPIcrea) 
Female: pCrea ≤ 62: CKD-EPIcrea = 144 * (pCrea/62)-0.329 * 0.993Age 
Female: pCrea > 62: CKD-EPIcrea = 144 * (pCrea/62)-1.209 * 0.993Age 
Male: pCrea ≤80: CKD-EPIcrea = 141 * (pCrea/80)-0.411 * 0.993Age 
Male: pCrea > 80: CKD-EPIcrea = 141 * (pCrea/80)-1.209 * 0.993Age 
 
 
 
 
Table 3. Cystatin C based eGFR equations 
Cystatin C equations 
CAPA[36] 
CAPAcysc = 130 * (pCysC)-1.069 * (Age)-0.117 -7 
CKD-EPI cystatin C (CKD-EPIcysc)[37] 
Male: cystatin C ≤ 0.8: CKD-EPIcysc = 133 * (pCysC/0.8)-0.499 * 0.996Age 
Male: cystatin C > 0.8: CKD-EPIcysc = 133 * (pCysC/0.8)-1.328 * 0.996Age 
Female: cystatin C ≤ 0.8: CKD-EPIcysc = 133 * (pCysC/0.8)-0.499 * 0.996Age * 0.932 
Female: cystatin C > 0.8: CKD-EPIcysc = 133 * (pCysC/0.8)-1.328 * 0.996Age * 0.932 
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Table 4. Creatinine and Cystatin C based eGFR equations 
 
 
 
 
  
Combination (Creatinine and Cystatin C) equations[37] 
Female:   
pCrea ≤ 62 & pCysC ≤ 0.8:  
CKD-EPIcrea+cysc  = 130 * (pCrea/62)-0.248 * (pCysC/0.8)-0.375 * 0.995Age 
  pCrea ≤ 62 & pCysC > 0.8:  
CKD-EPIcrea+cysc  = 130 * (pCrea/62)-0.248 * (pCysC/0.8)-0.711 * 0.995Age 
  pCrea > 62 & pCysC ≤ 0.8:  
CKD-EPIcrea+cysc  = 130 * (pCrea/62)-0.601 * (pCysC/0.8)-0.375 * 0.995Age 
  pCrea > 62 & pCysC > 0.8:  
CKD-EPIcrea+cysc  = 130 * (pCrea/62)-0.601 * (pCysC/0.8)-0. 711 * 0.995Age 
 
Male:   
pCrea ≤ 80 & pCysC < 0.8:  
CKD-EPIcrea+cysc  = 135 * (pCrea/80)-0.207 * (pCysC/0.8)-0. 375 * 0.995Age 
  pCrea ≤ 80 & pCysC > 0.8:  
CKD-EPIcrea+cysc  = 135 * (pCrea/80)-0.207 * (pCysC/0.8)-0.711 * 0.995Age 
  pCrea > 80 & pCysC < 0.8:  
CKD-EPIcrea+cysc  = 135 * (pCrea/80)-0.601 * (pCysC/0.8)-0. 375 * 0.995Age 
  pCrea > 80 & pCysC > 0.8:  
CKD-EPIcrea+cysc  = 135 * (pCrea/80)-0.601 * (pCysC/0.8)-0. 711 * 0.995Age 
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2.4 CIRCADIAN RYTHMS 
Circadian rhythms (from Latin: circa "about" and dies "day") refer to the near 24-hour 
physiological processes in humans. The functions of the body synchronize with each other 
and the external environment. This circadian pacemaker is located in the suprachiasmatic 
nuclei in the hypothalamus.  
The influence of alternating light and darkness and other cues in everyday healthy subjects 
helps to keep a fixed temporal relationship with the environment. If this relationship is 
affected the "clock" tends to drift with an intrinsic period of 24.18 hours[38]. Evidence 
supports that the pacemaker property remains stable with age.  
A study of circadian variability in healthy subjects showed that neither creatinine nor cystatin 
C differed significantly between night- and day-sleep conditions[39]. Concluding that 
sampling of these two markers does not have to be restricted to specific times of the day. 
The ICU milieu is quite harsh on the body and mind. Besides the critical illness affecting 
organ(s) patients are often medically sedated to various degrees. Ambient environment is 
often noisy and light. These factors alone can cause desynchronization of the circadian 
pacemaker[40]. Evidence has shown that patients with higher APACHE III scores show 
greater circadian phase displacement[41]. 
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3 AIMS OF THE THESIS 
The general aim was to investigate the performance of kidney function markers in patients 
during critical illness.  
 
Study I: To study the intraday variation of kidney function markers in ICU patients. 
 
Study II: To study the associations between creatinine & cystatin C and long-term mortality. 
 
Study III: To study the performance of commonly used estimated GFR equations in an ICU 
context. 
 
Study IV: To study the incidence of CKD both creatinine and cystatin C based. To investigate 
factors predictive of renal dysfunction at three months according to creatinine and cystatin C.
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4 SUBJECTS AND METHODS 
4.1 ETHICAL CONSIDERATIONS 
The Regional Ethics Committee of Stockholm approved studies I – IV. The studies were 
performed in compliance with the Helsinki Declaration of 1964 and its amendments. For 
study I and III written informed consent was obtained from patients or next of kin before 
enrollment. 
 
4.2 REGISTERS AND DATABASES 
The Swedish National Registration Number 
A unique Personal Identification Number (PIN)[42] is issued to all Swedish citizens at birth 
or upon immigration. It is used for interactions with government and private administrative 
agencies including health care. It allows for linkage with other registers e.g. The Cause of 
Death Register.  
 
The Cause of Death Register 
The Cause of Death Register was established in 1952 and is managed by the Swedish Board 
of Health and Welfare. It contains the time and cause of death for all residents who have been 
issued with a national identification number. The register is considered very reliable. Ref 
2010 socialstyrelsen dödorsaksstatistik[43].  
This database was used in study II and IV 
 
Centricity Clinisoft, The patient Database Management System in the ICU 
Centricity Clinisoft is a Patient Database Management System developed by GE Healthcare. 
It acquires and stores physiological data from patients as well as admission/discharge times, 
laboratory results, ventilator settings, diagnoses, and to a limited degree procedural codes and 
treatments.  
Clinisoft was incrementally introduced ICUs at Karolinska University Hospital starting in 
2005 and less than two years later implemented in all ICU departments. 
This database was used in study II and IV 
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EXCRETe  
The EXCRETe (EXtracorporeal Clearance & REsidual renal function during rrT) database is 
Excel based and includes patients with eGFR (MDRD estimate) > 60mL/min/1.73m2 on 
admission to ICU (CIVA) and with an expected length of stay above 24h. Exclusion criteria 
are patients with RRT treatment prior to ICU admission. The first EXCRETe patient was 
included November 2008.  
Data consists of daily scoring of RIFLE and AKIN (both creatinine and urine output criteria); 
SIRS; baseline characteristics APACHE II-score (Acute Physiology And Chronic Health 
Evaluation), ICU diagnoses; urinary output; blood pressure; biomarker concentrations; body 
weight; drug treatments.  
This database was used in study IV 
 
Take Care 
Take Care (CompuGroup Medical, Koblenz, Germany) is a hospital electronic health records 
system which is used by several hospitals and outpatient clinics in Sweden. It contains 
medical journals, laboratory results, consultant statements, and results from diagnostic tests. 
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4.3 SUMMARY OF STUDIES I – IV 
 
 Study I Study II Study III Study IV 
Data source General ICU and 
Neurosurgical 
ICU, TC, Clinisoft 
Clinisoft, DR, 
SNR 
General ICU and 
Neurosurgical ICU, 
TC, Clinisoft 
Clinisoft, Excrete, 
DR, SNR 
Design Single center 
Prospective cohort 
Single center 
Retrospective 
observational 
cohort 
Single center 
Prospective cohort 
Single center 
Prospective cohort 
Study period 2013-2014 2006 – 2013 2013-2014 2008-2011 
Number of 
subjects 
28 3077 30 274 
Outcome eGFR 
Creatinine 
Cystatin C 
Creatinine, 
Cystatin C, 
eGFR  
Death 
mGFR 
eGFR 
CKD at three 
months  
Death 
Analyses CV 
 
Multivariable 
survival 
model, HR,  
eGFR, 
Iohexol 
measurements of 
GFR 
Cox regression 
Kaplan Meier 
Logistic regression 
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4.4 STUDY I  
Design and study population 
The cohort consisted of 28 patients. The period of inclusion was between January 2013 and 
September 2014.  
Inclusion criteria were clinically stable patients treated at two intensive care units at 
Karolinska University Hospital. The patients had been treated at the ICU for a period longer 
than three days, and they were expected to stay at the ICU for additional 24h after inclusion, 
were not in a septic state, and did not require active fluid resuscitation.  
Exclusion criteria were patients under 18 years of age, unwillingness to participate (the 
patient him- or herself or next of kin), planned surgery during the time of the investigation, 
pregnancy, patients treated with renal replacement therapy, and patients who had been 
exposed to contrast media during the time of treatment in the ICU. 
 
Statistical analysis 
Continuous data are reported as mean or median. The coefficient of variation was defined as 
the standard deviation (SD) divided with the mean of all results for each patient.  
For estimating GFR for creatinine the CKD-EPI equation was used and for estimating GFR 
for cystatin C the CAPA equation was used. Additionally, a combination of creatinine and 
cystatin C formula was used. 
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4.5 STUDY II 
Design and study population 
A total of 3077 patients were included into the study 
during the period November 2006 – December 2013. All 
ICU admissions greater than 24 hours were eligible for 
inclusion. Using the Personal Identification Number 
patient data was linked with diagnosis data, pre- and post 
ICU laboratory data (TC), the Cause of Death Register, 
and with the Swedish Renal Registry. Thus allowing for 
evaluation of pre-ICU Charlson Comorbidity Index 
(Quan modification), exclusion of patients with ESRD 
prior to or within 14 days after ICU discharge, and 
patients who died in the ICU or within three days of 
discharge. (Figure 1) 
AKI was defined according to the Kidney Disease: 
Improving Global Outcomes criteria i.e. a 1.5 fold 
increase from baseline serum creatinine at ICU 
admission or an absolute creatinine increase of 26.5mcr 
mol/L within a 48 period. (Table 1) 
 
Statistical analysis 
Continuous variables were presented as median with 
interquartile range. Wilcoxon rank-sum test, Wilcoxon 
signed-rank test, and Fishers exact test were used for 
univariable comparisons. Fisher exact test was used for 
binary and continuous data. Kaplan-Meier plots of 
unadjusted survival data which were stratified by 
quartiles of creatinine and cystatin C.  
 
 
 
 
 
 
4771 ICU 
admissions of 
>24h in period  
17/10/2006-31/12/2013
3541 with discharge 
Cys-c 
measurement
3077 patients in 
final post-ICU 
survival analysis
3446 Patients 
without  ESRD 
before or 
immediately after 
ICU
111 with no 
linkage to 
mortality data
4258 First ICU 
admissions of >24h  
in time period
4660 with long-term 
mortality data
402 Re-admissions
575 with no Cys-c 
up to 2 days prior or 
one day after ICU 
discharge
95 registered with 
ESRD in SRR prior 
to admission or up 
to 14 days after ICU 
discharge
369 Died in ICU or 
within 3 days of ICU 
discharge (12%)
Figure 1. Study II – Patient selection flowchart. 
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4.6 STUDY III 
Design and study population 
The cohort consisted of 30 patients. The period of inclusion was between January 2013 and 
September 2014.  
Inclusion criteria were clinically stable patients treated at two intensive care units at 
Karolinska University Hospital. The patients had been treated at the ICU for a period longer 
than three days, and they were expected to stay at the ICU for additional 24h after inclusion, 
were not in a septic state, and did not require active fluid resuscitation.  
Exclusion criteria were patients under 18 years of age, unwillingness to participate (the 
patient him- or herself or next of kin), planned surgery during the time of the investigation, 
pregnancy, patients treated with renal replacement therapy, and patients who had been 
exposed to contrast media during the time of treatment in the ICU. 
 
Statistical analysis 
Five single markers estimating GFR equations were used. Three creatinine-based equations: 
MDRDCREA, LM-REVCREA, and CKD-EPICREA. Two cystatin C-based equations: CAPACYSC 
and CKD-EPICYSC.  
Three combined equations were used: CKD-EPICREA+CYSC, Mean of CAPA and LM-REV, 
and Mean of the two single-marker CDK-EPI equations.  
Continuous variables were presented as median with interquartile range and categorical 
variables as n (%). Bias was estimated with the median differences between eGFR and 
measured GFR. Precision was estimated as the interquartile range of the difference eGFR and 
mGFR. 95%-CI was estimated using Efron’s non-parametric bias corrected and accelerated 
(BCa) method.  
Accuracy was assessed as the absolute difference between eGFR and mGFR as well as the 
proportion of eGFR within 10%, 20% and 30% of mGFR presented as P10, P20, and P30 
respectively. CIs were assessed by using the binomial proportion Wilson score interval. 
Bland-Altman plots representing the agreement between eGFR and mGFR (presented as 
supplemental material to the article). 
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4.7 STUDY IV 
Design and study population 
1869 patients were admitted to the ICU during the study time. After exclusion, death, lost to 
follow-up, and patients not feeling well enough to attend the result was a prospective cohort 
of 274 patients. Study-inclusion period was between 2008 and 2010  
 
Figure 2. Flow chart showing selection and exclusion of patients in the follow-up cohort. White boxes: Entire ICU cohort, 
information derived from cross-matching with the ICU database and death register. Blue boxes: Data from the initial study 
database. Yellow boxes: Details of groups included in subanalyses. * Patients discharged when research staff were not 
working or who were transferred to other hospitals were not recruited[44]. 
 
Inclusion criteria were patients with AKI (defined according to RIFLE[1] which was the 
classification system used at the time of the study) during admission to and alive at discharge 
from the general ICU at Karolinska University Hospital Solna.  
Exclusion criteria were age younger than 18 and older than 100 years. Death within three 
months after discharge from ICU. Presence of CKD or ESRD prior to ICU admission. Loss 
of recruitment due to lack of research staff availability during weekends, public holidays, and 
the period from February to April 2010.  
At three months follow-up patients were referred to either nephrology or ICU outpatient 
clinics where creatinine and cystatin C were measured. Patients who did not attend follow-up 
were reviewed and values from visits to primary care were collected.   
 
One-year mortality was 18.7% in non-AKI patients and
28.2% in all AKI patients. Two-year mortality was signifi-
cantly higher for patients with creatinine-based CKD
AKI
N = 834
Patients admitted to ICU
N = 1869
No AKI
N = 1042
Death on ICU
N = 92
AKI admissions alive at
discharge
N = 742
Recruited
N = 336
Not recruited due to logistical reasons ∗
N = 291
Lost to follow-up
N = 41
Multiple admissions for eligible patients removed
N = 55
Death during first 3 months or prior to follow-up
N = 21
Follow-up N = 274
(Table 1)
At least one biomarker measured
N = 252 included in regression analysis
Initially included in
excrete
N = 451
Both creatinine and cystatin C available
N = 201
Subanalyses 
only follow-up
between 2–7
months
(22 excluded)
Prior CKD
N = 60
Figure 1: Flow chart showing selection and exclusion of patients in the follow-up cohort. White boxes: entire ICU cohort, information
derived from cross-matching wit the ICU database a d death register; blue boxes: data fr m the initial study database; yellow boxes: details
of groups included in subanalyses. ∗Patients discharged hen research staff were not working or who were transfe red to other hospitals
were not recruited.
Table 2: Median eGFR in 201 patients where both variables were measured with follow-up between 2 and 7 months.
GFR estimates at 3-month follow-up, according to creatinine- and cystatin C-based equations
N ! 201 (mL/min/1.73m2) Median IQR Minimum Maximum P compared to L-M estimate
Lund-Malmo¨ 74.6 55.9–94.3 18.5 132.2 Reference
MDRD 81.6 58.6–106.8 7.0 225.2 <0.001
CKD-EPI-Cr 86.0 59.6–101.4 6.6 139.6 <0.001
CKD-EPI-cy 51.4 35.8–69.9 9.1 138.3 <0.001
CKD-EPI-Cr-cy 64.5 46.7–83.5 7.28 137.5 <0.001
L-M! Lund-Malmo¨ formula. MDRD!modified diet in renal disease formula.
0
10
20
30
40
50
60
70
Lund-Malmö MDRD CKD-EPI-Cr Cystatin C Combined
formula
30.8 25.8 25.8
63.7
42.2
Proportion of patients with CKD
KDIGO (Stage 3–5) by eGFR method
Figure 2: Categorisation of patients by CKD group (stage 3–5) at
follow-up according to the method of GFR estimation, in 201
patients where both variables were measured.
Table 3: Categorisation of the cohort according to the AKD group,
in 201 patients where creatinine and cystatin C were both measured
with follow-up between 2 and 7 months.
Acute kidney disease grade N %
0 82 40.8
0 B-C 81 40.3
1 26 12.9
2 8 3.98
3 4 1.99
AKD grade 1–3 38 18.9
4 Critical Care Research and Practice
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Statistical analysis 
 
Continuous variables were presented as median with interquartile range. Categorical data 
expressed as counts with percentage. Distributions of continuous variables were compared 
using Mann-Whitney’s test while Fisher's test was used for comparing means of binary 
variables. A two-sided p-value < 0.05 was considered statistically significant. 
For estimating creatinine-based GFR the MDRD, LM-REV, and CDK-EPI while cystatin C-
based GFR was calculated with the CDK-EPI (cystatin C). The composite CKD-EPI 
(creatinine, cystatin C) was also used.  
The patients were classified as having CKD at three months according to KDOQI stages of 
chronic kidney disease. Urine-based eGFR was not used[45]. Patients without prior CKD 
were classified as having AKD if their follow-up creatinine was >1.5x their baseline 
creatinine.  
Modeling was done in the following way. Death was considered a censoring event. A Cox 
regression model weighted for the inverse probability of dying after discharge and before 
three months. It was adjusted for covariates found to be independently associated with death 
before follow-up. Variables included in the final model were: age, sex, and maximum RIFLE 
stage. This model was used in all regression analyses.  
Logistic regression was used to identify covariates which affected the risk of the binary 
outcome of CKD (<60ml/min/1.73m2) according to creatinine and cystatin C. Kaplan-Meier 
was used to calculate survival probabilities, differences between groups were tested using the 
log-rank test. The models were assessed using Somers' d, Bayesian-, and Akaike information 
criterion (BIC, AIC). 
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5 RESULTS AND DISCUSSION 
5.1 STUDY I 
Results 
The coefficient of variation was marginally larger for creatinine than for cystatin C (3.70% 
respective 3.66%).  CV for the corresponding creatinine and cystatin C eGFR were 2.00% 
respective 4.60%. See table 6. 
Comparing the eGFR, cystatin C consequently showed values nearly half of that of 
creatinine. 
Table 5.  
 Median 
concentration 
Median eGFR 
(mL/min/1.73m^2) 
Median CV 
(conc) 
Median CV 
eGFR 
Creatinine 50 umol/L 102.8  3.70% 2.00% 
Cystatin C 1.44 mg/L 47.2  3.66% 4.60% 
 
Discussion 
This study showed that the median coefficient of variation of creatinine, cystatin C, and of 
eGFR (both creatinine and cystatin C based) was below 5%. This means that 95% of the 
results will vary with less than 10% between sampling times.  
Differences larger than 10% between sampling times are therefore more likely to be an 
indication of changes in biomarker levels due to disease and or treatment. 
  
 26 
5.2 STUDY II 
Results 
At 90-days after ICU discharge 318 (10.3%) had died and at one year this number had risen 
to 536 (17.4%). (Table 7). Nonsurvivors who more often developed AKI were older, had 
higher Simplified Acute Physiology Score-3 (SAPS-3) and had more comorbidities. From 
ICU admission to discharge creatinine fell and cystatin C increased in value.  
Cystatin C and creatinine differed distinctly in their association with mortality at 90-day and 
1-year at ICU discharge Table 8. Comparing the unadjusted quartile 1 for creatinine (13.6%) 
and cystatin C (5.6%) and marks a low-risk population for cystatin C.  
When fitting creatinine and cystatin C to penalized splines in a multivariable survival model 
(sex, age-stratification, comorbidity index) it shows that cystatin C was near linearly related 
to an increased hazard ratio for death. Creatinine showed a less linear relationship with a 
more flat curve (Figure 4).  
Analyzing both creatinine and cystatin C together in a new multivariable survival model (sex, 
age-stratification, comorbidity index) showed a strong association between increasing 
cystatin C and hazard ratio for death. The opposite for creatinine which now showed a lower 
hazard ratio with increasing discharge concentration. (Figure 5). 
Cystatin C based eGFR 
identified, at discharge, 
1,362 patients (44%) with a 
GFR < 60ml/min/1.73m^2 
where creatinine-based 
eGFR identified 794 (26%).  
In a subset of 516 patients 
with a length of stay of 7 
days or greater creatinine, 
cystatin C, and C-reactive 
protein (CRP) were 
compared (Figure 2). 
Creatinine had a clear 
downward slope while 
cystatin C progressively 
rose. CRP showed a bi-phasic profile that did not correlate with the two endogenous renal 
filtration markers.  
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Figure 3. Time-course of creatinine, cystatin C, and C-Reactive Protein in 516 patients 
with ICU admissions greater than 7 days. (Median % change from d1 value and 
binomial estimate of the 95% CI of the Median). 
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Table 6 Demographics and Renal Filtration Markers in Survivors and Non-survivors 
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TABLE 1.  Demographics and Renal Filtration Markers in Concentrations in Survivors and 
Nonsurvivors
Characteristics
All Patients, n (%)  
or Median (IQR)
Survived 1 yr, n (%)  
or Median (IQR)
Died by 1 yr, n (%)  
or Median (IQR)
Number 3,077 (100) 2,542 (82.6) 535 (17.4)
Age 59 (41–70) 56 (38–68) 69 (60–76)
Male sex 1,899 (61.7) 1,559 (61.3) 340 (63.4)
ICU length of stay (hr) 58 (34–120) 58 (33–119) 62 (37–125)
Simplified Acute Physiology Score-3a 37 (26–50) 35 (24–48) 47 (36–57)
Medical 1,348 (43.8) 1,039 (40.9) 309 (57.8)
Surgical 959 (31.2) 776 (30.5) 183 (34.2)
Trauma 770 (25.0) 727 (28.6) 43 (8.0)
Infection (primary diagnosis) 704 (22.8) 520 (20.5) 184 (34.4)
Closest to ICU admission creatinine 0.98 (0.74–1.41) 0.96 (0.74–1.38) 1.14 (0.80–1.73)
Closest to ICU admission cystatin Ca 1.01 (0.75–1.53) 0.94 (0.72–1.38) 1.36 (1.02–1.93)
Peak creatinine 1.06 (0.79–1.66) 1.03 (0.77–1.56) 1.30 (0.87–2.15)
Peak cystatin C 1.20 (0.83–1.93) 1.11 (0.80–1.76) 1.69 (1.19–2.52)
Discharge creatinine 0.83 (0.63–1.20) 0.80 (0.62–1.13) 1.02 (0.69–1.57)
Discharge cystatin C 1.10 (0.80–1.63) 1.01 (0.77–1.48) 1.57 (1.12–2.16)
Discharge eGFR (creatinine) 92 (58–112) 95 (65–115) 70 (41–96)
Discharge eGFR (cystatin C) 68 (37–105) 76 (44–109) 40 (26–64)
Renal replacement therapy in ICU 238 (7.7) 177 (7.0) 61 (11.4)
Comorbidities    
 Myocardial infarction 240 (7.82) 163 (6.41) 77 (14.39)
 Congestive heart failure 289 (9.42) 189 (7.44) 100 (18.69)
 Peripheral vascular disease 330 (10.75) 256 (10.07) 74 (13.83)
 Stroke 237 (7.72) 169 (6.65) 68 (12.71)
 Dementia 32 (1.04) 11 (0.43) 21 (3.93)
 Pulmonary disease 405 (13.2) 308 (12.12) 97 (18.13)
 Rheumatic disease 102 (3.32) 76 (2.99) 26 (4.86)
 Peptic ulcer disease 94 (3.06) 60 (2.36) 34 (6.36)
 DM without complication 310 (10.1) 243 (9.56) 67 (12.52)
 DM with complication 112 (3.65) 76 (2.99) 36 (6.73)
 Hemiplegia or paraplegia 87 (2.83) 69 (2.71) 18 (3.36)
 Renal disease 142 (4.63) 102 (4.01) 40 (7.48)
 Liver disease mild 108 (3.52) 94 (3.7) 14 (2.62)
 Liver disease moderate-severe 39 (1.27) 20 (0.79) 19 (3.55)
 Nonmetastatic cancer 478 (15.58) 339 (13.34) 139 (25.98)
 Metastatic cancer 317 (10.33) 188 (7.4) 129 (24.11)
 HIV 11 (0.36) 9 (0.35) 2 (0.37)
(Continued)
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covariates were handled by stratification for that variable. Based 
on general population data, we hypothesized that creatinine or 
cystatin C would be nonlinearly related to risk of death; accord-
ingly, these variables were fitted to a penalized spline. The degree 
of curve smoothing in the final model was determined by an 
algorithm based on minimization of Akaike’s Information Cri-
terion. Finally, we included creatinine and cystatin C in a single 
age-, sex-, and comorbidity-adjusted multivariable model to 
explore the additive effects of these markers in combination.
RESULTS
Demographics
After exclusions, 3,077 survivors were included for primary analy-
sis (Fig. S1, Supplemental Digital Content 1, http://links.lww.com/
CCM/C667). By 90 days after ICU discharge, 318 (10.3%) died ris-
ing to 536 (17.4%) at 1 year. Nine patients developed new ESRD in 
the year after ICU discharge. Nonsurvivors were older, had greater 
comorbidity and higher Simplified Acute Physiology Score-3, more 
often developed AKI, and required renal replacement therapy. 
Patients dying in the year after ICU discharge had higher admission, 
peak and ICU discharge creatinine than long-term survivors, but 
these differences were more marked for cystatin C at all timepoints 
(Table 1). Importantly, while creatinine fell, from ICU admission to 
discharge, cystatin C rose over the same period (Table 1).
Renal Function Markers and Mortality After ICU 
Discharge
Cystatin C and creatinine at ICU discharge differed distinctly 
in their association with mortality over the next 90 and 365 
days (Table 2). The lowest cystatin C quartile defined a low-
risk population with a 5.6% 1-year mortality, compared with 
13.6% in the lowest creatinine quartile. Overall, rates of death 
were well separated with increasing rates of death between 
quartiles of discharge cystatin C, whereas for creatinine, only 
the upper quartile was separated (Fig. 1).
Multivariable Survival Analysis
To detect nonlinear relationship between filtration markers and 
mortality risk, creatinine and cystatin C were fitted to penalized 
splines in a multivariable survival model including sex, strati-
fied for age, and comorbidity index. Increasing cystatin C was 
near-linearly related to increasing hazard ratio (HR) for death; 
conversely, creatinine demonstrated a J-shaped relationship 
(Fig. 2). These relationships persisted when patients with or 
without AKI were considered separately (Fig. S2, Supplemental 
Digital Content 1, http://links.lww.com/CCM/C667). Consid-
ering both creatinine and cystatin C together in a new multi-
variable model including age, sex, and comorbidity, increasing 
cystatin C remained strongly associated with increasing HR 
for death; however, higher creatinine was then associated with 
“lower” hazard of death at all creatinine levels (Fig. 3).
Relationship Between Cystatin C- and Creatinine-
Based eGFR
Median eGFR at ICU discharge based on creatinine was greater 
than using cystatin C (92 vs 68 mL/min/1.73 m2; p < 0.001). 
Using cystatin C for eGFR identified 1,362 patients (44%) less 
than 60 mL/min/1.73 m2 at ICU discharge compared with only 
794 (26%) using creatinine-based eGFR. Despite a substan-
tially larger population with low eGFR, there was similar mor-
tality in the cystatin C group with eGFR less than 60 compared 
with that defined by creatinine eGFR (cystatin C: 386/1,362; 
28% vs creatinine: 233/794; 29%) (Table S1, Supplemental 
Digital Content 1, http://links.lww.com/CCM/C667).
We examined cystatin C/creatinine divergence during ICU 
stay by comparing ratio of creatinine to cystatin C eGFR for 
different durations of ICU admission (Fig. S3, Supplemental 
Charlson Comorbidity Index (Quan)    
 0 1,591 (51.71) 1,472 (57.91) 119 (22.24)
 1–2 781 (25.38) 623 (24.51) 158 (29.53)
 3–4 314 (10.21) 219 (8.62) 95 (17.76)
 5–6 293 (9.52) 177 (6.96) 116 (21.68)
 > 6 98 (3.19) 51 (2.01) 47 (8.79)
AKI    
 No AKI 2,157 (70.10) 1,848 (72.70) 309 (57.76)
 AKI-1 408 (13.26) 319 (12.55) 89 (16.64)
 AKI-2 172 (5.59) 116 (4.56) 56 (10.47)
 AKI-3 340 (11.05) 259 (10.19) 81 (15.14)
AKI = acute kidney injury, DM = diabetes mellitus, eGFR = estimated glomerular filtration rate, IQR = interquartile range.
a Values available in 3,013 patients for Simplified Acute Physiology Score-3 and 3,070 for closest to admission cystatin C.
TABLE 1.  (Continued). Demographics and Renal Filtration Markers in Concentrations in 
Survivors and Nonsurvivors
Characteristics
All Patients, n (%)  
or Median (IQR)
Survived 1 yr, n (%)  
or Median (IQR)
Died by 1 yr, n (%)  
or Median (IQR)
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Table 7 Crude mortality and Adjusted Hazard Ratios for Death over 90-days and 1-Year Follow-up After Critical Illness 
Associated with plasma Cystatin C and Creatinine Measurements Near ICU Discharge 
 
 
 
Figure 4. Crude mortality in the year after ICU discharge stratified by quartiles of creatinine or cystatin C at ICU discharge. 
 
Figure 5. Age- and sex-adjusted hazard ratios for survival in the year after ICU discharge.  
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Digital Content 1, http://links.lww.com/CCM/C667). In 
admissions lasting 1–2 days, the median ratio was 1.01 (IQR, 
0.87–1.24). However, with longer admissions, eGFR by creati-
nine was consistently greater than eGFR cystatin C. For ICU 
admissions of greater than 20 days, values of eGFR (creatinine) 
were a median of 2.1-fold (IQR, 1.7–2.8) greater than corre-
sponding eGFR (cystatin C). Finally, to illustrate the timing 
of changes in creatinine and cystatin C after ICU admission, 
we examined changes in creatinine, cystatin C, and C-reactive 
protein (CRP) over the first 7 days of ICU admission and at 
ICU discharge in a subset of 516 patients with ICU admis-
sions of greater than or equal to 7 days. In this analysis, cre-
atinine progressively fell, whereas at the same time, cystatin 
C rose (Fig. S4, Supplemental Digital Content 1, http://links.
lww.com/CCM/C667). During this period, CRP had a biphasic 
profile and did not correlate with the two endogenous renal 
filtration markers.
To explore the discrepancy of cystatin C and creatinine at 
ICU discharge, we considered 743 patients without AKI in the 
ICU (where ICU discharge renal function would be expected 
to be similar to follow-up) who had a creatinine measure-
ment in the 30–365 days after discharge and survived to 1 
year. In this group, we compared cystatin C and creatinine 
eGFR at ICU discharge against follow-up creatinine eGFR (at 
a median of 267 d [IQR, 145–334] after hospital discharge). 
GFR based on cystatin C better agreed with CKD categoriza-
tion at follow-up, particularly in the GFR range 30–60. In con-
trast, discharge creatinine eGFR overestimated follow-up GFR 
in all CKD categories (Fig. S5, Supplemental Digital Content 
1, http://links.lww.com/CCM/C667; Table S2, Supplemental 
Digital Content 1, http://links.lww.com/CCM/C667).
TABLE 2. Crude Mortality and Adjusted Hazard Ratios for Death Over 90-Day and 1-Year 
Follow-Up After Critical Illness Associated With Plasma Cystatin C and Creatinine 
Measurements Near ICU Discharge
 
Unadjusted Post-ICU Survival by Quartile of Cystatin C or 
Creatinine
Adjusted Hazard Ratio 75th Relative to 25th 
CentileQuartile 1 Quartile 2 Quartile 3 Quartile 4
Cystatin C
 Values (mg/L) 0.20–0.80 0.80–1.10 1.10–1.63 1.63–8.48 1.63 vs 0.80
 90-d mortality 2.6% 6.2% 11.8% 21.0% 2.23 (1.63–3.02)
 365-d mortality 5.6% 11.0% 21.2% 32.0% 1.78 (1.46–2.18)
Creatinine
 Values (mg/dL) 0.1–0.63 0.63–0.83 0.83–1.20 1.20–11.55 1.20 vs 0.63
 90-d mortality 8.4% 6.3% 9.9% 17.0% 1.09 (0.89–1.33)
 365-d mortality 13.6% 12.4% 17.3% 26.7% 1.03 (0.87–1.21)
Figure 1. Crude mortality in the year after ICU discharge stratified by quartiles (Qs) of creatinine or cystatin C at ICU discharge.
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Digital Content 1, http://links.lww.com/CCM/C667). In 
admissions lasting 1–2 days, the median ratio was 1.01 (IQR, 
0.87–1.24). However, with longer admissions, eGFR by creati-
nine was consistently greater than eGFR cystatin C. For ICU 
admissions of greater than 20 days, values of eGFR (creatinine) 
were a median of 2.1-fold (IQR, 1.7–2.8) greater than corre-
sponding eGFR (cystatin C). Finally, to illustrate the timing 
of changes in creatinine and cystatin C after ICU admission, 
we examined changes in creatinine, cystatin C, and C-reactive 
protein (CRP) over the first 7 days of ICU admission and at 
ICU discharge in a subset of 516 patients with ICU admis-
sions of grea er than or equal to 7 days. In this analysis, cre-
atinine progressively fell, whereas at the same time, cystatin 
C rose (Fig. S4, Supplemental Digital Content 1, http://links.
lww.com/CCM/C667). During this period, CRP had a biphasic 
profile and did not correlate with the two endogenous renal 
filtration markers.
To explore the discrepancy of cystatin C and creatinine at 
ICU discharge, we considered 743 patients without AKI in the 
ICU (where ICU discharge renal function would be expected 
to be similar to follow-up) who had a creatinine measure-
ment in the 30–365 days after discharge and survived to 1 
year. In this group, we compared cystatin C and creatinine 
eGFR at ICU discharge against follow-up creatinine eGFR (at 
a median of 267 d [IQR, 145–334] after hospital discharge). 
GFR based on cystatin C better agreed with CKD categoriza-
tion at follow-up, particularly in the GFR range 30–60. In con-
trast, discharge creatinine eGFR overestimated follow-up GFR 
in all CKD categories (Fig. S5, Supplemental Digital Content 
1, http://links.lww.com/CCM/C667; Table S2, Supplemental 
Digital Content 1, http://links.lww.com/CCM/C667).
TABLE 2. Crude Mortality and Adjusted Hazard Ratios for Death Over 90-Day and 1-Year 
Follow-Up After Critical Illness Associated With Plasma Cystatin C and Creatinine 
Measurements Near ICU Discharge
 
Unadjusted Post-ICU Survival by Quartile of Cystatin C or 
Creatinine
Adjusted Hazard Ratio 75th Relative to 25th 
CentileQuartile 1 Quartile 2 Quartile 3 Quartile 4
Cystatin C
 Values (mg/L) 0.20–0.80 0.80–1.10 1.10–1.63 1.63–8.48 1.63 vs 0.80
 90-d mortality 2.6% 6.2% 11.8% 21.0% 2.23 (1.63–3.02)
 365-d mortality 5.6% 11.0% 21.2% 32.0% 1.78 (1.46–2.18)
Creatinine
 Values (mg/dL) 0.1–0.63 0.63–0.83 0.83–1.20 1.20–11.55 1.20 vs 0.63
 90-d mortality 8.4% 6.3% 9.9% 17.0% 1.09 (0.89–1.33)
 365-d mortality 13.6% 12.4% 17.3% 26.7% 1.03 (0.87–1.21)
Figure 1. Crude mortality in the year after ICU discharge stratified by quartiles (Qs) of creatinine or cystatin C at ICU discharge.
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Figure 2. Age- and sex-adjusted hazard ratios for survival in the year after ICU discharge fitted with penalized spline regression for ICU discharge 
creatinine and cystatin C. Stratified Cox model (strata: comorbidity index category [0, 1–2, 3–4, 5–6, and > 6] and octiles of age). Values plotted from the 
fifth to 95th centiles the predictor variable and distribution of values within this range are marked above the x-axis. Reference is 25th centile value set to 
hazard ratio equals to 1st, 25th, 50th, and 75th centiles are marked with vertical lines.
Figure 3. Including cystatin C and creatinine together in a single Cox proportional hazard survival model, age- and sex-adjusted hazard ratios for survival 
in the year after ICU discharge fitted with penalized spline regression for ICU discharge creatinine adjusted for cystatin C and cystatin C adjusted for 
creatinine. Stratified Cox model (strata: comorbidity index category [0, 1–2, 3–4, 5–6, and > 6] and octiles of age). Values plotted from the fifth to 95th 
centiles the predictor variable and distribution of values within this range is marked above the x-axis. Reference is 25th centile value set to hazard ratio 
equals to 1st, 25th, 50th and 75th centiles are marked with vertical lines.
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Figure 6. Including cystatin C and creatinine together in a single Cox proportional hazard survival model, age- and sex-
adjusted hazard ratios for survival in the year after ICU discharge fitted with penalized spline regression for ICU discharge 
creatinine adjusted for cystatin C and cystatin C adjusted for creatinine. 
 
 
Discussion 
Creatinine and cystatin C diverge during ICU admission as seen in the subgroup of 516 
patients in figure 2. At the time of ICU discharge, the median difference between eGFR 
(cystatin C) and eGFR (creatinine) was 24ml/min/1.73m2. So clearly one, or both, fail to 
reflect the GFR.  
Assuming that both kidney function markers are similarly affected by renal function then the 
difference must be explained by a difference in the rate of generation of the markers during 
critical illness.  
Age- and sex-adjusted hazard ratios for survival in the year after ICU discharge is shown in 
figure 4. The linearity presented by cystatin C shows a clear increased risk of death not 
produced by creatinine.  
At shorter ICU admissions creatinine and cystatin C eGFR were similar.  
A subgroup of 743 patients without AKI in the ICU survived up to one year after hospital 
discharge. Creatinine was measured between 30 to 365 days. Comparing these patients out-
of-hospital eGFR (creatinine) with the discharge eGFR (both creatinine and cystatin C) 
showed that cystatin C based eGFR at ICU discharge was closer to the creatinine-based 
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Figure 2. Age- and sex-adjusted hazard ratios for survival in the year after ICU discharge fitted with penalized spline regression for ICU discharge 
creatinine and cystatin C. Stratified Cox model (strata: comorbidity index category [0, 1–2, 3–4, 5–6, and > 6] and octiles of age). Values plotted from the 
fifth to 95th centiles the predictor variable and distribution of values within this range are marked above the x-axis. Reference is 25th centile value set to 
hazard ratio equals to 1st, 25th, 50th, and 75th centiles are marked with vertical lines.
Figure 3. Including cystatin C and creatinine together in a single Cox proportional hazard survival model, age- and sex-adjusted hazard ratios for survival 
in the year after ICU discharge fitted with penalized spline regression for ICU discharge creatinine adjusted for cystatin C and cystatin C adjusted for 
creatinine. Stratified Cox model (strata: comorbidity index category [0, 1–2, 3–4, 5–6, and > 6] and octiles of age). Values plotted from the fifth to 95th 
centiles the predictor variable and distribution of values within this range is mark d above the x-axis. Ref rence is 25th c ntile value set to hazard ratio 
equals to 1st, 25th, 50th and 75th centiles are marked with vertical lines.
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eGFR measured after discharge. This was significant for the GFR interval 30 to 
60ml/min/1.73m2.  
In other words, at ICU discharge the cystatin C predicts creatinine eGFR better than 
creatinine does at ICU discharge for this subgroup. 
The reduction in creatinine generation with muscle wasting may explain why lower discharge 
creatinine is not associated with better prognosis.  
When combining both markers in a single Cox proportional hazard survival model (figure 5) 
cystatin C remained strongly associated with mortality and increasing creatinine was 
consistently associated with lower mortality. Potentially reflecting lower mortality in patients 
with less muscle wasting. 
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5.3 STUDY III 
Results 
The performance of both single and 
combination GFR endogenous 
biomarker estimates is shown in table 9. 
The creatinine-based eGFR equations 
(MDRD, LM-REV, and CKD-EPIcr) 
overestimated mGFR while cystatin C-
based eGFR equations (CAPA and 
CKD-EPIcysc) underestimated mGFR.  
Single marker estimates: LM-REV 
demonstrated the lowest bias 
(8.0ml/min/1.73m2) and best p30 
accuracy (66.7%). MDRD performed 
the worst with the greatest bias, the 
lowest precision, and the lowest 
accuracy.  
The combined eGFR equations 
underestimated measured GFR (median of 7.4 to 11.5ml/min/1.73m2). When compared with 
the single marker estimates the combined eGFR equations showed consistently higher p30, 
p20 accuracy (figure 6) although they were inferior to the cystatin C single marker in their 
precision. 
 
Table 8. Performance of single marker and combined marker equations calculated from the differences between estimated 
and measured GFR (estimated minus measured GFR, i.e. positive values if the estimate is higher than the measured). 
 
 
 
 
Table 2. Performance of single marker and combined marker equations calculated from the differences between estimated and measured 
GFR (estimated minus measured GFR, i.e. positive values if the estimate is higher than the measured).
Single marker equations Combined marker equations
Performance MDRDCREA LM-REVCREA CAPACYSC CKD-EPICREA CKD-EPICYSC CKD-EPICREA+CYSC MEANCAPA+LM-REV MEANCKD-EPI 
Bias
Median differencea, ml/min/1.73 m2
(95% CI)
35.77
(18.1 to 47.1)
8.0
(-4.17 to 16.2)
- 26
(-30.4 to -19.7)
14
(2.16 to 24.1)
-25
(-32.3 to -20.3)
-10
(-17.1 to -0.648)
-11.5
(-19.6 to -0.0541)
-7.38
(-14.7 to 4.42)
Median percentage difference
(95% CI)
49.5
(24.1 to 78.9)
9.3
(-4.8 to 24.4)
-32.2
(-41.4 to -25.1)
18.7
(1.2 to 33.5)
-33.1
(-44.7 to -24.6)
-12.1
(-19.2 to -1.2)
-13.8
(-19.4 to -0.04)
-8.7
(-15.9 to 4.98)
Precision
IQR of differencesb, ml/min/1.73 m2
(95% CI)
45.5
(24.95 to 80.41)
31.6
(19.9 to 44.4)
18.3
(11.5 to 33.3)
35.9
(24.0 to 50.1)
18.0
(8.6 to 29.3)
20.8
(15.8 to 32.5)
22.9
(15.7 to 31.7)
25.0
(18.8 to 35.6)
Accuracy
Median absolute percentage difference
(95% CI)
49.5
(24.6 to 77.7) 
17.1
(9.8 to 27.3)
32.2
(24.6 to 40.6)
19.6
(12.4 to 33.5) 
33.1
(23.7 to 42.2)
14.5
(10.5 to 24.6)
17.5
(12.8 to 21.4)
16.1
(10.6 to 21.9)
p30, %c
(95% CI)
43.3
(27.4 to 60.8)
66.7
(48.8 to 80.8)
46.7
(30.2 to 63.9)
63.3
(45.5 to 78.1)
43.3
(27.4 to 60.8)
80.0
(62.7 to 90.5)
86.7
(70.3 to 94.7)
86.7
(70.3 to 94.7)
p20, %c
(95% CI)
23.3
(12.0 to 40.9)
56.7
(39.2 to 72.6)
23.3
(11.8 to 40.9)
53.3
(36.1 to 69.8)
20.0
(9.5 to 37.3)
60.0
(42.3 to 75.4)
60.0
(42.3 to 75.4)
60.0
(42.3 to 75.4)
CI, confidence interval; IQR, interquartile range
Measured GFR denotes the iohexol-based measurement of GFR.
aDifference in estimated minus measured GFR.
bInterquartile rage (IQR) defined as the range between Q1 and Q3.
cp30 and p20 refer to the percentage of GFR estimates within 30% and 20% of measured GFR, respectively
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Figure 7. Accuracy of each of the eGFR equations expressed as 
percentage within 10%, 20% or 30% (p10, p20, p30 respectively) of 
measured GFR 
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Discussion 
Iohexol measurements were performed after a median length in the ICU of 16 days (10 - 21). 
Which is a long time considering how fast immobilization or partial immobilization affects 
muscle volume. The creatinine-based equations overestimated and the cystatin C-based 
equations underestimated GFR. The "native" combined (CKD-EPIcysc,cr) and the two 
additional combined equations demonstrated sufficient accuracy with p30 >= 80% but 
underestimated GFR by 8 to 14%  
A study by Björk showed that combining creatinine and cystatin C improved GFR 
estimations in adult non-ICU patients with results of p30 >= 90%[46] 
Suggesting that neither the pure creatinine nor the pure cystatin C-based equations for 
estimating GFR are particularly useful in critically ill patients in ICU with longer treatment 
times. The combined formulas strengthen the accuracy though they still tend to underestimate 
GFR.  
 
  
  33 
5.4 STUDY IV 
Results 
 ICU mortality among AKI patients 
was 11.1% Follow-up occurred at 
101.5 days (median, IQR 89.5 - 126).  
The median age of recruited AKI 
patients was 64 years (41.6% female). 
Median SAPS-2 was 48.5.  
 
Measured baseline creatinine was 64 
µmol/l and estimated creatinine 
baseline creatinine was 88µmol/l. 
Cystatin C was available in 211 
patients with a median of 1.33mg/l.  
 
Using cystatin C-based estimate 
63.7% of patients fulfilled the criteria 
for KDIGO CKD stage 3 or higher. Of 
the creatinine-based estimators; LM-
REV 30.8%, MDRD 25.8%, and 
CKD-EPI(creatinine) 25.8% fulfilled 
the CKD criteria. The composite 
CKD-EPI(creatinine, cystatin C) identified 42.2% of patients having CKD.  
47 (18.7%) of 252 patients, who had follow-up creatinine measured between two and seven 
months, fulfilled the AKD criteria. Of 201 patients with both markers available, 38 (18.9%) 
fulfilled the CKD criteria (table 10). 
 
 
 
CKD diagnosis based on cystatin C-
based eGFR was associated with 
increasing age, diabetes, and elevated 
discharge cystatin C. The risk of developing CKD according to creatinine-based eGFR was 
associated with increasing age and female sex in the logistic regression models.  
cystatin C. Odds ratios are presented. The models were
assessed using Somers’ d as well as Bayesian and Akaike
information criteria (BIC and AIC).
Survival probabilities were calculated using the
Kaplan–Meier method, and differences between groups were
tested using the log-rank test.
4. Results
During the study time, 1869 ICU patients were admitted and
41.4% fulfilled RIFLE criteria for AKI. ICU mortality was
11.1% among AKI patients. Of those alive at discharge, 336
entered the study, 41 lost to follow-up, and 21 died before
follow-up (Figure 1). Reasons for loss to follow-up included
moving outside of the region, diagnosis of dementia, social
problems, and feeling too unwell to attend. Table 1 presents
baseline characteristics of the remaining recruited patients.
Details of the entire ICU cohort are given in Table S2. The
median follow-up was 101.5 days (IQR 89.5–126). Admission
reasons for the recruited patients are displayed in Figure S3.
Recruited AKI patients had a median age of 64 years,
and 41.6% were female; the median SAPS-2 score was 48.5
(Table 1). The studied groups were similar in age, gender
distribution, and SAPS-2 score to nonrecruited AKI patients
(included patients who died before follow-up) (Table S2).
Recruited patients had a longer length of stay (LOS), a lower
proporti n received invasive ventila o , and themedian daily
diuresis was higher than that in the nonrecruited group.
Patients without AKI were younger, had shorter LOS,
and lower SAPS-2 scores than AKI patients. Non-AKI pa-
tients had a lower frequency of invasive ventilation and
lower creatinine, urea, and cystatin C throughout their ICU
stay (Table S2).
Baseline creatinine was measured in 56.9% of patients,
median was 64 µmol/l (IQR 50.5–76), and median estimated
baseline creatinine was 88 µmol/l (71–97) (Table 1). The
median follow-up creatinine was 76 µmol/l (IQR 59–96)
(Table S4). Cystatin C was available in 211 patients with
a median of 1.33mg/l (IQR 1.09–1.73).
GFR estimates for patients where both creatinine and
cystatin C were assessed are presented in Table 2.The Lund-
Malmo¨ formula gave the lowest median GFR estimate of the
creatinine-based formulae (74.6 compared with
81.6mL/min/1.73m2 for MDRD; P≤ 0.001), which is nearer
to the cystatin C median GFR (51.4mL/min/1.73m2.). Es-
timates obtained using the combined cystatin C and cre-
atinine formula (64.5mL/min/1.73m2) lie in between
estimates from individual markers.
5. Patients Meeting Chronic Kidney
Disease Criteria
63.7% of patients fulfilled the c iteria fo KDIGO CKD stage
3 or greater at first follow-up using cystatin C-based esti-
mates, whereas when creatinine-based formulae were ap-
plied 3 fulfilled CKD criteria using L-M and 25.8%
according to both MDRD and CKD-EPI-based estimates.
(Figure 2 and Table S5). The combined formula identified
42.2% of patients as having CKD.
6. Acute Kidney Disease Diagnosis
In 252 pati nts in hom follow-up creatinine was obtained
between 2 and 7 months, 47 (18.7%) fulfilled AKD criteria. Of
201 patients with both biomarkers available (the same group
as eGFR analysis), 38 (18.9%) met AKD criteria (Table 3).
Incidence of AKD at ICU discharge could not be de-
scribed because the groups’ median length of stay (6 days) was
less than the minimum time when AKD may be diagnosed (7
days after AKI insult). However, analysis showed that, on the
day of discharge, 204 patients (60.7%) fulfilled AKD criteria.
Multivariate logistic regression estimated the risk of
CKD (eGFR <60mL/min/1.73m2) according to creatinine
(MDRD) and cystatin C. Two models for creatinine-based
CKD are shown in Table 4. Both models include age and
female gender, and model-1 also includes cystatin C at
di charge; this performed some hat better when assessed
using Somers’ d, AIC, and BIC than model-2 which used
discharge creatinine. Covariates associated with 3-month
cystatin C-eGFR (Table 5) were age, cystatin C at discharge,
and diabetes. Univariate sensitivity analysis showed that the
likelihood of diagnosis with CKD according to cystatin C
and the likelihood of AKD increased significantly if known
baseline creatinine was used rather than estimated baseline,
and this effect disappeared in multivariate analysis.
TABLE 1: Baseline characteristics of all recruited AKI patients.
Baseline characteristics of all recruited
AKI patients (274)
Median values
and IQR unless
otherwise stated
Median age (years) (IQR) 64 (53–72)
Sex (female), N (%) 114 (41.6)
Length of stay (days) (IQR) 6 (3–12)
SAPS-2 score (IQR) 48.5 (38–64)
Invasive ventilation, N (%) 109 (40)
Dialysis on ICU, N (%) 66 (24)
Maximum urea (mmol/l) (IQR) 15.7 (9–25.2)
Baseline creatinine
N measured (%) 156 (56.9)
Measured (µmol/l) (IQR) 64 (50.5–76)
Estimateda (µmol/l) (IQR) 88 (71–97)
N! 146
Admission creatinine (µmol/l) (IQR) 135 (104–213)
Maximum creatinine (µmol/l) (IQR) 169.5 (122–263)
Last ICU creatinine (µmol/l) (IQR) 107 (72–149.5)
Admission cystatin C (mg/l) (IQR) 1.58 (1.1–2.35)
Maximum cystatin C (mg/l) (IQR) 2.14 (1.44–3.04)
Last ICU cystatin C (mg/l) (IQR) 1.65 (1.23–2.21)
Discharge creatinine/cystatin C ratio (IQR) 7.1 (5.2–9.2)
COPD 53 (14.5)
Diabetes mellitus I and II 54 (19.7)
Cardiovascular disease 90 (33.0)
Hypertension 120 (44.0)
Liver failure 99 (36.0)
Haematological malignancy 19 (6.9)
Other malignancies 84 (30.6)
Heart failure 38 (13.8)
MDRD!modified diet in renal disease formula. aCreatinine was estimated
using the Modified Diet in Renal Disease (MDRD) formula using an
expecting GFR of 75ml/kg/min/1.73m2.
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Table 9. Baseline characteristics of all recruited AKI patients. 
One-year mortality was 18.7% in non-AKI patients and
28.2% in all AKI patients. Two-year mortality was signifi-
cantly higher for patients with creatinine-based CKD
AKI
N = 834
Patients admitted to ICU
N = 1869
No AKI
N = 1042
Death on ICU
N = 92
AKI admissions alive at
discharge
N = 742
Recruited
N = 336
Not recruited due to logistical reasons ∗
N = 291
Lost to follow-up
N = 41
Multiple admissions for eligible patients removed
N = 55
Death during first 3 months or prior to follow-up
N = 21
Follow-up N = 274
(Table 1)
At least one biomarker measured
N = 252 included in regression analysis
Initially included in
excrete
N = 451
Both creatinine and cystatin C available
N = 201
Subanalyses 
only follow-up
between 2–7
months
(22 excluded)
Prior CKD
N = 60
Figure 1: Flow chart showing selection and exclusion of patients in the follow-up cohort. White boxes: entire ICU cohort, information
derived from cross-matching with the ICU database and death register; blue boxes: data from the initial study database; yellow boxes: details
of groups included in subanalyses. ∗Patients discharged when research staff were not working or who were transferred to other hospitals
were not recruited.
Table 2: Median eGFR in 201 patients where both variables were measured with follow-up between 2 and 7 months.
GFR estimates at 3-month follow-up, according to creatinine- and cystatin C-based equations
N ! 201 (mL/min/1.73m2) Median IQR Minimum Maximum P compared to L-M estimate
Lund-Malmo¨ 74.6 55.9–94.3 18.5 132.2 Reference
MDRD 81.6 58.6–106.8 7.0 225.2 <0.001
CKD-EPI-Cr 86.0 59.6–101.4 6.6 139.6 <0.001
CKD-EPI-cy 51.4 35.8–69.9 9.1 138.3 <0.001
CKD-EPI-Cr-cy 64.5 46.7–83.5 7.28 137.5 <0.001
L-M! Lund-Malmo¨ formula. MDRD!modified diet in renal disease formula.
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Lund-Malmö MDRD CKD-EPI-Cr Cystatin C Combined
formula
30.8 25.8 25.8
63.7
42.2
Proportion of patients with CKD
KDIGO (Stage 3–5) by eGFR method
Figure 2: Categorisation of patients by CKD group (stage 3–5) at
follow-up according to the method of GFR estimation, in 201
patients where both variables were measured.
Table 3: Categorisation of the cohort according to the AKD group,
in 201 pa ients where cr atinine and cystati C both measure
with follow-up between 2 and 7 m nths.
Acute kidney disease grade N %
0 82 40.8
0 B-C 81 40.3
1 26 12.9
2 8 3.98
3 4 1.99
AKD grade 1–3 38 18.9
4 Critical Care Research and Practice
Table 10. Categorisation of the cohort according to the AKD group. 
201 patients where creatinine and cystatin C were both measured at 
follow-up (between 2 to 7 months). 
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One-year mortality for all AKI patients was 28.2% (18.7% in non-AKI patients). Two-year 
mortality for patients classified as AKD was 16.7% and 11.2% for patients without AKD (not 
significant). The difference in mortality between patients classified as having CKD according 
to creatinine or cystatin C based CKD was not significant.  
 
Discussion 
This study showed that renal dysfunction was common among patients with AKI in the ICU 
at follow-up at three months after discharge. I.e., CKD is more common than our national 
registers. Could it be underdiagnosed even in the non-AKI population? A control group could 
have shead light on that question. If composite eGFR equations were used it could mean that 
CKD incidence is even higher. In study III of this thesis, it was shown that cystatin C-based 
markers (admittedly in ICU context only) underestimate GFR. In study II we showed that 
creatinine was poorly related to the risk of death but cystatin C (at ICU discharge) on the 
other hand showed to be better at predicting creatinine-based eGFR. This was significant for 
the GFR interval 30-60ml/min/1.73m2. An inherent weakness of creatinine especially in the 
ICU is the coupling to sarcopenia. Cystatin C on the other hand seems to increase 
successively during the entire ICU admission. 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
Study I and III 
Both studies originate from the same cohort from two ICUs in the same hospital. Recruitment 
was restricted to weekdays (only a few patients were included during weekends) and 
tampered by planned or acute treatments/examinations. Also, laboratory unavailability was a 
restricting factor. Selection bias may have been the most pronounced systematic error 
introduced into these two studies. We manually selected each patient according to in- and 
exclusion criteria.  
The method by which GFR is measured in study III was associated with a certain amount of 
"eyeballing" so to speak. To interpret the elimination curves we needed to find where the 
curve transitions from being dominated by the fast distribution phase to the slow elimination 
phase. This usually happens after approximately 1-2 hours but differs depending on the 
individual patient's kidney function and distribution volume. 
 
Study II 
Study II was a single center retrospective observational study and as such a multicenter study 
would be needed to confirm the findings. All patients in the Clinisoft database during the 
study period were included.  
 
However, generalizability is limited to the fact that it is a single center study. Cystatin C 
measurements were limited to the ICU, and the discharge measurement reflects relative 
clinical stability since we expect the renal recovery to be ongoing at this point. An increased 
cystatin C production that is independently associated with increased mortality cannot be 
excluded. 
 
Study IV 
 
This study was a single center investigation with patients from only one general ICU. The 
patient selection was affected by staff being unavailable and weekend or evening discharges. 
In the absence of baseline creatinine, it was estimated by use of the eGFR 75 approach as 
recommended by the ADQI group utilizing the MDRD equation. This method may introduce 
a misclassification of, e.g. patients with undiagnosed preexisting CKD thereby 
overestimating the incidence of AKI. The loss to follow-up could very well have added to the 
selection bias. 
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6.2 CONCLUSIONS 
The general aim was to investigate the performance of kidney function markers in patients 
during critical illness. The main findings were as follows. 
 
Study I: The coefficient of variation was greater for creatinine than for cystatin C. Both 
markers are within the normally acceptable range.  
 
Study II: Levels of cystatin C after critical illness were strongly associated with 90-day and 1-
year mortality both in AKI and non-AKI patients. Creatinine was poorly related to the risk of 
death. Creatinine had little value as a prognostic marker in the majority of patients.  
 
Study III: Combined formulas using both creatinine and cystatin C enables the best 
agreement between estimated and measured GFR. 
 
Study IV: The incidence of CKD (eGFR<60) in ICU patients three months after AKI was 
25.8% when using creatinine-based eGFR and 63.7% using cystatin C-based eGFR.  
Creatinine-defined CKD at follow-up was predicted by age, discharge cystatin C, discharge 
creatinine, and female sex. 
Cystatin C-defined CKD at follow-up was predicted by age, discharge cystatin C, CRRT in 
ICU, and diabetes. 
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Don't do it!". But we both did.  
Thank you to all of you whom I forgot to mention.  
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